Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
March 17, 2021 07:00 ET
|
Imara, Inc.
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower...
Imara Reports Full Year 2020 Financial Results and Business Highlights
March 05, 2021 07:00 ET
|
Imara, Inc.
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical...
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
February 26, 2021 21:30 ET
|
Imara, Inc.
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
January 20, 2021 07:00 ET
|
Imara, Inc.
BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
January 06, 2021 07:00 ET
|
Imara, Inc.
Promising reductions in rate of VOCs/SCPCs observed in monotherapy IMR-687 treated patients vs. placebo Biomarker data from both monotherapy IMR-687 and combination IMR-687+HU groups show improvement...
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
December 07, 2020 07:00 ET
|
Imara, Inc.
Preliminary data as of August 2020 from ongoing Phase 2a open label extension trial showed increases in HbF percentage and F-cells after approximately six months of treatment Case reports showed...
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
November 30, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
November 17, 2020 07:00 ET
|
Imara, Inc.
BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
November 05, 2020 07:00 ET
|
Imara, Inc.
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease ...